# Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

> **NCT00319969** · PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 76 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Amrubicin
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT00319969
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-07
- **Final completion:** 2009-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2009-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319969, "Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00319969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*